
States take the reins on insurance reform
Driving The Day
STATE CRACKDOWN — Congressional lawmakers have tried and failed several times to push through a bipartisan, health-industry-backed bill that would speed up health insurers' prior authorization processes for certain prescription drugs and medical services. Congress will launch another attempt this year, but a growing number of blue and red states have taken the matter into their own hands.
In 2024, at least 10 states passed laws to reform the prior authorization process, according to a report from the American Medical Association. Insurers use prior authorization to control costs.
The state action continues to increase in 2025. Within the past few months, states including California, Connecticut, Hawaii, Iowa, New Jersey, North Carolina and North Dakota have either proposed or enacted reforms aimed at simplifying and streamlining prior authorization. And other states, including Illinois, Georgia, Texas, Rhode Island, Minnesota and Florida, have proposed cracking down on the use of artificial intelligence in prior authorization decisions.
Why it matters: The uptick in state prior authorization reforms comes as health insurers have come under intense public and congressional scrutiny over how often they deny care, especially in the wake of the fatal shooting of UnitedHealthcare CEO Brian Thompson in December. The use of AI to deny care has also put insurers in the hot seat, with UnitedHealth Group facing a lawsuit over allegations that it used AI to wrongfully deny care to Medicare Advantage patients.
The state reforms also come amid a lack of congressional action on the issue, despite widespread bipartisan and industry support for reforming the prior authorization process, which can sometimes be slow and administratively burdensome — impeding patients' access to necessary medical care.
Even so: State power to regulate prior authorization is limited. While states have considerable authority over insurance companies operating within their markets, the federal government has jurisdiction over self-insured employer health plans and Medicare Advantage plans.
'State action is important, but it's not complete without federal action in some ways, because it's a federal requirement for employers, for self-insured and for Medicare Advantage plans, that state activity is not going to touch them,' said Kaye Pestaina, director of KFF's Program on Patient and Consumer Protections.
Background: Last week, bipartisan lawmakers in the House and the Senate reintroduced the Improving Seniors' Timely Access to Care Act — a bill that would streamline prior authorization for older adults enrolled in Medicare Advantage. Despite widespread support from lawmakers, providers, doctors and insurers — and estimated to cost $0 by the last Congress — the repeatedly introduced bill has yet to pass.
WELCOME TO WEDNESDAY PULSE. A new study found that teens living in areas with more access to cannabis retailers face significantly higher rates of mental health issues. Send your tips, scoops and feedback to khooper@politico.com and ccirruzzo@politico.com, and follow along @Kelhoops and @ChelseaCirruzzo.
At the Agencies
A THREAT TO MEDICAL JOURNALS — HHS Secretary Robert F. Kennedy Jr. is escalating his war on institutions he says are influenced by pharmaceutical companies, Chelsea reports.
On Tuesday, Kennedy, speaking on the 'Ultimate Human' podcast — a show hosted by a longevity expert that focuses on optimizing health — threatened to stop government scientists from publishing their work in major medical journals, including The New England Journal of Medicine, JAMA and The Lancet. He said the influential medical journals are 'corrupt' and publish studies that pharmaceutical companies fund and approve.
'Unless those journals change dramatically, we are going to stop NIH scientists from publishing in them, and we're going to create our own journals in-house,' he said. NIH is the world's largest funder of health research.
Key context: Kennedy's comments come days after his Make America Healthy Again Commission released a report saying overprescribed medications could be driving a rise in chronic disease in children, suggesting the pharmaceutical industry has an outsize influence on doctors and scientists. It also comes after both JAMA and NEJM received letters from the Department of Justice probing them for partisanship.
A JAMA spokesperson said the journal had nothing to add when asked about Kennedy's remarks, while NEJM and The Lancet did not respond to requests for comment. HHS also did not respond to requests for comment.
Even so: Kennedy's stance conflicts with that of his NIH director, Dr. Jay Bhattacharya, who recently told a reporter with POLITICO sister publication WELT that he supports academic freedom, which 'means I can send my paper out even if my bosses disagree with me.'
UPPING STATE OVERSIGHT — The Centers for Medicare and Medicaid Services is warning states against using federal dollars to pay for the health care of undocumented immigrants.
In a Tuesday letter, the agency notified states it's ramping up financial oversight of state Medicaid expenditures to comply with President Donald Trump's executive order on 'Ending Taxpayer Subsidization of Open Borders.' The increased oversight includes 'focused reviews' of certain state spending reports and in-depth reviews of state financial management systems. The agency will also review eligibility rules in federal regulations and 'be proposing revisions as may be necessary.'
'Medicaid is not, and cannot be, a backdoor pathway to subsidize open borders,' said CMS Administrator Mehmet Oz in a news release. 'States have a duty to uphold the law and protect taxpayer funds. We are putting them on notice — CMS will not allow federal dollars to be diverted to cover those who are not lawfully eligible.'
Key context: Undocumented immigrants are generally not eligible for Medicaid, though some states have used state-only funds to expand coverage to noncitizens.
The increased oversight from CMS comes as Republicans' 'big, beautiful bill,' which passed the House, includes a provision that would penalize states that have expanded Medicaid coverage to undocumented immigrants by reducing the federal matching rate for the Medicaid expansion population for those states.
Vaccines
CDC'S COVID VAX CHANGE — The CDC no longer recommends that 'healthy' children and pregnant women receive the Covid-19 vaccine, a controversial change that's perplexed some public health experts, POLITICO's Sophie Gardner and David Lim report.
On Tuesday, HHS Secretary Robert F. Kennedy Jr. announced the guidance change in a post on social media platform X, saying 'it's common sense and it's good science.'
'We're now one step closer to realizing President Trump's promise to make America healthy again,' Kennedy said in a video, standing beside FDA Commissioner Marty Makary and NIH Director Jay Bhattacharya. Kennedy cited 'a lack of any clinical data to support the repeat booster strategy in children.'
Background: The CDC had recommended the vaccine for everyone at least 6 months old. Kennedy has long maintained that Covid vaccines aren't safe, despite the medical consensus that they are.
Most Americans have stopped getting Covid vaccines. The most recent CDC data says about 1 in 8 children under 18 have received the latest shot, while fewer than 1 in 4 adults ages 18 and older have.
Key context: The change bucks the CDC's precedent for updating vaccine recommendations, which typically takes place after a panel of experts votes on proposed changes.
'I'm disturbed for a couple reasons,' said Dr. Georges Benjamin, executive director of the American Public Health Association, which represents public health workers. 'I don't believe that they followed the normal process whereby you bring the advisory committees into this decision.'
Other experts raised concerns about the public health implications of the decision.
'I'm perplexed by this decision,' said Mark Turrentine, an OB-GYN and professor at Baylor College of Medicine in Houston. 'A lot of pregnant people died of Covid, especially during the Delta wave. And we know Covid still hasn't gone away. And we know pregnant people are a high-risk group. And we have a lot of data that the vaccine provides strong protection for both the mother and the baby.'
WHAT WE'RE READING
POLITICO's Victor Goury-Laffont reports on France advancing an assisted-dying bill in a historic vote.
STAT's Jason Mast reports on what one child's success story means for the CRISPR gene-editing industry.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Shares of UnitedHealth Group (NYSE:UNH) soared on Friday with news that several prominent investors had purchased shares of the health insurance company. A well-known member of Congress is also buying up shares and adding to her position. Marjorie Taylor Greene Scoops Up More Shares Rep. Marjorie Taylor Greene (R-Ga.) bought more UnitedHealth stock, according to new filings reported on the Benzinga Government Trades page. In a new filing, Greene revealed four new investments made on Aug. 4, which are listed below: Bought $1,000 to $15,000 in AbbVie Inc (NYSE:ABBV) stock Bought $1,000 to $15,000 in United Parcel Service (NYSE:UPS) stock Bought $1,000 to $15,000 in UnitedHealth stock Bought $50,000 to $100,000 in US Treasury Bills The latest purchase follows several other investments in UnitedHealth stock by Greene in 2025. The Congresswoman also disclosed buying shares in May. On May 14, Greene purchased $15,000 to $50,000 worth of shares. On May 16, Greene purchased shares worth between $1,000 and $15,000. Trending: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — With a current share price of $307.83 at the time of writing and a share range of $236.95 to $242.25 on Aug. 4, the Congresswoman is up at least 27.1% from that trade made less than two weeks ago. The other two trades this year have not performed as well. Here are the price ranges from the two May dates and return for Greene based on the highest price of the stock that day: May 14: $307.11 to $322.94, -4.&% May 16: $269.14 to $294.49, +4.5% The Congresswoman could have had better returns depending on the price paid. UnitedHealth stock fell sharply around the time of the May 16 purchase, with the company announcing CEO Andrew Witty was stepping down and that they were withdrawing guidance. Why It's Important The latest disclosure from Greene follows filings from prominent investors, such as Warren Buffett and Michael Burry, which revealed long positions in the health insurance company. Buffett revealed a stake of more than five million shares in filings from Berkshire Hathaway Inc (NYSE:BRK) (NYSE:BRK). Big Short investor Burry, who leads Scion Asset Management, revealed a long position in UnitedHealth via shares and call options. Citron Research also revealed Friday that Andrew Left was long UnitedHealth stock. Burry and Left are best known for short positions against stocks, making their long stakes in the future success of UnitedHealth particularly interesting to investors. Greene is also not the only member of Congress buying UnitedHealth shares. With investigations into the company, members of Congress may face a conflict of interest if they are required to decide against the health insurance Congressional Trades While Greene doesn't have the same trading record as Buffett and Burry, she has become one of the most followed members of Congress when it comes to stock trading. The Congresswoman's purchases of Palantir stock this year have performed well, but they also raise potential conflicts of interest on the House Committee on Homeland Security. In 2024, Greene's return of +30.2% ranked 23rd among members of Congress according to an annual report from UnusualWhales tracking performance. A bill to ban members of Congress from trading has gained momentum and could change the future of trading for Greene and other members. Greene previously brushed off criticism on the timing of her trades this year, saying she has a portfolio manager who handles her stock transactions. The Congresswoman praised her portfolio manager's timing of buying the dip earlier this year. Benzinga recently polled readers to gauge their stance on a potential ban on Congress members stock trading. 'Should members of Congress be allowed to buy and sell stocks, options and ETFs?' Benzinga asked. These were the results: They should not be allowed to trade stocks, options or ETFs: 43% They should be allowed to trade as long as they report within 24 hours: 24% They should only be allowed to trade ETFs and mutual funds: 14% They should be allowed to trade as long as they report in 45 days: 11% They should only be allowed to trade stocks: 8% The poll found that 43% of readers support an outright ban on members of Congress trading stocks, options, or ETFs. Eleven percent voted that the current rules should be left alone, with a 45-day disclosure window. Read Next: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo: Shutterstock This article Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry originally appeared on Sign in to access your portfolio


Time Business News
5 hours ago
- Time Business News
Debbie Wasserman Schultz on the Legislative Frontlines
Debbie Wasserman Schultz has built a reputation in Congress as a determined advocate for civil rights, healthcare reform, and public safety. Representing Florida in the U.S. House of Representatives since 2005, she has consistently championed legislation that addresses the needs of vulnerable communities while working to strengthen the nation's democratic values. Throughout her career, Debbie Wasserman Schultz has been a strong defender of civil rights. She has taken bold positions on issues ranging from voting rights to LGBTQ equality. As a member of Congress, she has supported legislation aimed at expanding voter access, opposing discriminatory practices, and ensuring that every citizen has an equal voice in the democratic process. Her advocacy extends to protecting religious and ethnic minorities. Most recently, she has been at the forefront of efforts to create a national strategy to combat antisemitism, working across party lines to address the rise in hate crimes and extremist rhetoric. She views these initiatives not only as a matter of protecting one community, but as a fundamental defense of American democracy. For Debbie Wasserman Schultz, healthcare reform has always been more than a talking point. A breast cancer survivor herself, she has been a leading voice for policies that expand access to preventive care and early detection services. Her leadership on the EARLY Act has helped fund breast cancer education programs for young women, potentially saving thousands of lives through increased awareness and timely screenings. She has also recently introduced the Reducing Hereditary Cancer Act, a bipartisan bill designed to make genetic cancer testing more accessible to Americans who are at risk. By removing financial and coverage barriers, she hopes to create a healthcare system that focuses on prevention and equity, ensuring no patient is denied care because of cost or insurance limitations. In addition to her work on civil rights and healthcare, Debbie Wasserman Schultz has been an advocate for public safety measures that protect communities while respecting individual rights. She has supported common-sense gun safety reforms, investments in law enforcement training, and improved coordination among public safety agencies. Her legislative work also extends to protecting children and families. She has championed laws like the Virginia Graeme Baker Pool and Spa Safety Act, which addresses child drownings by requiring safety standards for public pools and spas. These efforts reflect her broader commitment to legislation that has a tangible impact on everyday lives. While Congress is often marked by partisan gridlock, Debbie Wasserman Schultz has shown an ability to collaborate with colleagues from both sides of the aisle. Her bipartisan efforts on anti-hate initiatives, healthcare reform, and safety legislation demonstrate her belief that meaningful change requires cooperation and dialogue, even among political opponents. This approach has allowed her to move forward on initiatives that might otherwise stall in a divided political climate. By focusing on shared values such as safety, health, and equality, she has been able to advance legislation that benefits a broad range of Americans. As she continues her work in Congress, Debbie Wasserman Schultz remains committed to her core mission: defending civil rights, improving healthcare access, and safeguarding communities. She has made it clear that she sees these priorities as interconnected, with each influencing the strength and resilience of the nation as a whole. Her ongoing legislative efforts, from combating hate crimes to expanding medical testing access, are grounded in a belief that the government should be both responsive and proactive in addressing the needs of its people. This vision, combined with her experience and willingness to work across political divides, positions her as a significant force in shaping policy on some of the most pressing issues facing the country today. For constituents in Florida and for Americans across the nation, Debbie Wasserman Schultz continues to serve as a steadfast advocate, ensuring that civil rights, healthcare, and public safety remain at the top of the congressional agenda. TIME BUSINESS NEWS


Axios
6 hours ago
- Axios
UnitedHealth is unpopular, but its stock suddenly isn't
UnitedHealth Group's public reputation is still reeling, yet its battered stock has been something that more and more investors can't seem to resist. Why it matters: Recent interest in its stock, from everyday investors to Wall Street's titans, shows that investors have no issues looking past public sentiment when they see a path to share recovery. Catch up quick: Even since the December killing of its top insurance executive, Brian Thompson, UnitedHealth has borne the brunt of a wave of social media outrage over insurers' roles in coverage denials and rising costs — criticism UnitedHealth has insisted is misguided. Still, executives acknowledged in April that the company had an image problem, and needed to communicate better with their customers about its coverage decisions and processes. In May, it pulled its full-year earnings outlook and made a change at CEO. In July, it confirmed an earlier report that the DOJ was looking into its Medicare billing practices, and warned that escalating medical costs would continue to drag down earnings. The impact: Its stock has taken a beating — it's fallen 55% since the public backlash in December. The latest: That slide has drawn the attention of some pretty big investors, most notable among them, Warren Buffett's Berkshire Hathaway — which on Thursday disclosed having bought more than 5 million shares in the company as of the end of the June. Berkshire wasn't alone. David Tepper's hedge fund Appaloosa Management and Michael Burry's Scion Assets Management (made famous in "The Big Short") also disclosed having bought positions. That sent UnitedHealth's shares up 12% Friday. Regular investors have been buying in, too. Interactive Brokers listed UnitedHealth as the second largest net buying position on its platform in the first week of August. Charles Schwab listed it as one of the five most popular names among its retail clients in July, among Nvidia, Tesla, Palantir and Amazon.